High materiality8/10
Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
Why it may matterVerify against the original reporting
very_bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Wells Fargo upgrades VRDN with a bullish outlook as Lumvoa launch KPIs likely to outperform. Target 31; current price 18.58; price change since signal -0.28.
- Target $31; current $18.58; -$0.28 since signal.
Key facts
- 01
Target: $31
- 02
Posted price: $18.58
- 03
Analyst firm: Wells Fargo
- 04
Analyst: Derek Archila
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.